{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T22:57:43Z","timestamp":1776380263293,"version":"3.51.2"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:00:00Z","timestamp":1644278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadinternational.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD International"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jdin.2022.01.011","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T23:17:36Z","timestamp":1645053456000},"page":"178-186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Cutaneous reactions to COVID-19 vaccines: A review"],"prefix":"10.1016","volume":"7","author":[{"given":"See Wei","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yew Chong","family":"Tam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiu Ming","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jdin.2022.01.011_bib1","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1002\/jmv.26922","article-title":"Vaccination hesitancy and the \u201cmyth\u201d on mRNA-based vaccines in Italy in the COVID-19 era: does urgency meet major safety criteria?","volume":"93","author":"Chirumbolo","year":"2021","journal-title":"J Med Virol"},{"key":"10.1016\/j.jdin.2022.01.011_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100780","article-title":"Correcting COVID-19 vaccine misinformation: lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members","volume":"33","author":"Hotez","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"27","key":"10.1016\/j.jdin.2022.01.011_bib3","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jdin.2022.01.011_bib4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"10267","key":"10.1016\/j.jdin.2022.01.011_bib5","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jdin.2022.01.011_bib6","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1473-3099(20)30987-7","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Wu","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.jdin.2022.01.011_bib7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2021.03.092","article-title":"Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases","volume":"85","author":"McMahon","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"24","key":"10.1016\/j.jdin.2022.01.011_bib8","first-page":"e98","article-title":"Delayed large local reactions to mRNA vaccines","volume":"384","author":"Baeck","year":"2021","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jdin.2022.01.011_bib9","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1001\/jama.2021.3976","article-title":"Acute allergic reactions to mRNA COVID-19 vaccines","volume":"325","author":"Blumenthal","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jdin.2022.01.011_bib10","doi-asserted-by":"crossref","DOI":"10.1177\/21501327211024431","article-title":"COVID arm: delayed hypersensitivity reactions to SARS-CoV-2 vaccines misdiagnosed as cellulitis","volume":"12","author":"Lindgren","year":"2021","journal-title":"J Prim Care Community Health"},{"issue":"8","key":"10.1016\/j.jdin.2022.01.011_bib11","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/jamadermatol.2021.2114","article-title":"Incidence of cutaneous reactions after messenger RNA COVID-19 vaccines","volume":"157","author":"Robinson","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"8","key":"10.1016\/j.jdin.2022.01.011_bib12","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1111\/all.14839","article-title":"Skin tests in urticaria\/angioedema and flushing to Pfizer-BioNTech SARS-CoV-2 vaccine: limits of intradermal testing","volume":"76","author":"Bianchi","year":"2021","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.jdin.2022.01.011_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00403-021-02190-6","article-title":"COVID-19\/SARS-CoV-2 virus spike protein-related delayed inflammatory reaction to hyaluronic acid dermal fillers: a challenging clinical conundrum in diagnosis and treatment","volume":"314","author":"Munavalli","year":"2022","journal-title":"Arch Dermatol Res"},{"issue":"9","key":"10.1016\/j.jdin.2022.01.011_bib14","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1111\/jocd.14312","article-title":"Hyaluronic acid soft tissue filler delayed inflammatory reaction following COVID-19 vaccination\u2014a case report","volume":"20","author":"Michon","year":"2021","journal-title":"J Cosmet Dermatol"},{"issue":"8","key":"10.1016\/j.jdin.2022.01.011_bib15","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1111\/ced.14784","article-title":"COVID-19 vaccine-induced Stevens\u2013Johnson syndrome","volume":"46","author":"Dash","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jdin.2022.01.011_bib16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jdcr.2021.05.010","article-title":"A case of severe cutaneous adverse reaction following administration of the Janssen Ad26.COV2.S COVID-19 vaccine","volume":"13","author":"Lospinoso","year":"2021","journal-title":"JAAD Case Rep"},{"issue":"1","key":"10.1016\/j.jdin.2022.01.011_bib17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jaad.2021.09.002","article-title":"Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: a registry-based study","volume":"86","author":"McMahon","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jdin.2022.01.011_bib18","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/ced.14970","article-title":"Abrupt onset of Sweet syndrome, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and erythema multiforme: unravelling a possible common trigger, the COVID-19 vaccine","volume":"47","author":"Sechi","year":"2022","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.jdin.2022.01.011_bib19","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1111\/jdv.17757","article-title":"Generalized erythema multiforme-like skin rash following the first dose of COVID-19 vaccine (Pfizer-BioNTech)","volume":"36","author":"Kim","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"10.1016\/j.jdin.2022.01.011_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.4947","article-title":"Erythema multiforme major following SARS-CoV-2 vaccine","volume":"9","author":"Saibene","year":"2021","journal-title":"Clin Case Rep"},{"issue":"11","key":"10.1016\/j.jdin.2022.01.011_bib21","first-page":"e466","article-title":"Atypical erythema multiforme related to BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine","volume":"60","author":"Bonino","year":"2021","journal-title":"Int J Dermatol"},{"issue":"7","key":"10.1016\/j.jdin.2022.01.011_bib22","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/ced.14714","article-title":"A flare of pre-existing erythema multiforme following BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine","volume":"46","author":"Lavery","year":"2021","journal-title":"Clin Exp Dermatol"},{"issue":"7","key":"10.1016\/j.jdin.2022.01.011_bib23","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1111\/jdv.17225","article-title":"Prompt onset of Rowell\u2019s syndrome following the first BNT162b2 SARS-CoV-2 vaccination","volume":"35","author":"Gambichler","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jdin.2022.01.011_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18176\/jiaci.0757","article-title":"Viral-like reaction or hypersensitivity? Erythema multiforme minor reaction and moderate eosinophilia after\u00a0receiving Pfizer-BioNTech BNT162b2 (mRNA-based SARS-CoV-2 vaccine)","volume":"32","author":"de Las Vecillas","year":"2022","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"7","key":"10.1016\/j.jdin.2022.01.011_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-243173","article-title":"Acute encephalitis, myoclonus and Sweet syndrome after mRNA-1273 vaccine","volume":"14","author":"Torrealba-Acosta","year":"2021","journal-title":"BMJ Case Rep"},{"issue":"10","key":"10.1016\/j.jdin.2022.01.011_bib26","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1111\/all.14981","article-title":"Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine","volume":"76","author":"Darrigade","year":"2021","journal-title":"Allergy"},{"issue":"11","key":"10.1016\/j.jdin.2022.01.011_bib27","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3390\/vaccines9111212","article-title":"Sweet syndrome following SARS-CoV2 vaccination","volume":"9","author":"Baffa","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"10","key":"10.1016\/j.jdin.2022.01.011_bib28","doi-asserted-by":"crossref","first-page":"5718","DOI":"10.1002\/jmv.27175","article-title":"AstraZeneca (AZD1222) COVID-19 vaccine-associated adverse drug event: a case report","volume":"93","author":"Capassoni","year":"2021","journal-title":"J Med Virol"},{"issue":"7","key":"10.1016\/j.jdin.2022.01.011_bib29","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1111\/jdv.17221","article-title":"Lichen planus arising after COVID-19 vaccination","volume":"35","author":"Hiltun","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.jdin.2022.01.011_bib30","doi-asserted-by":"crossref","first-page":"e729","DOI":"10.1111\/jdv.17504","article-title":"New-onset cutaneous lichen planus triggered by COVID-19 vaccination","volume":"35","author":"Merhy","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"10.1016\/j.jdin.2022.01.011_bib31","doi-asserted-by":"crossref","first-page":"e546","DOI":"10.1111\/jdv.17342","article-title":"Pityriasis rosea-like eruptions following vaccination with BNT162b2 mRNA COVID-19 vaccine","volume":"35","author":"Cyrenne","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jdin.2022.01.011_bib32","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1111\/bjd.20143","article-title":"Pityriasis rosea-like eruption after Pfizer-BioNTech COVID-19 vaccination","volume":"185","author":"Carballido V\u00e1zquez","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jdin.2022.01.011_bib33","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jdcr.2021.04.032","article-title":"Widespread annular eruption after Ad26.COV2.S COVID-19 vaccine","volume":"13","author":"Song","year":"2021","journal-title":"JAAD Case Rep"},{"issue":"9","key":"10.1016\/j.jdin.2022.01.011_bib34","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamadermatol.2021.2474","article-title":"Association of facial pustular neutrophilic eruption with messenger RNA-1273 SARS-CoV-2 vaccine","volume":"157","author":"Merrill","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"10","key":"10.1016\/j.jdin.2022.01.011_bib35","first-page":"e632","article-title":"Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine","volume":"35","author":"Krajewski","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jdin.2022.01.011_bib36","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"10249","key":"10.1016\/j.jdin.2022.01.011_bib37","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.jdin.2022.01.011_bib38","first-page":"e98","article-title":"Delayed large local reactions to mRNA vaccines","volume":"384","author":"Baeck","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jdin.2022.01.011_bib39","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1001\/jamadermatol.2021.1214","article-title":"Delayed localized hypersensitivity reactions to the Moderna COVID-19 vaccine: a case series","volume":"157","author":"Johnston","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"8","key":"10.1016\/j.jdin.2022.01.011_bib40","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/cea.12520","article-title":"Anaphylaxis and cardiovascular disease: therapeutic dilemmas","volume":"45","author":"Lieberman","year":"2015","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"10.1016\/j.jdin.2022.01.011_bib41","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.jaip.2019.10.027","article-title":"Biphasic reactions in emergency department anaphylaxis patients: a prospective cohort study","volume":"8","author":"Liu","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"10.1016\/j.jdin.2022.01.011_bib42","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1002\/jmv.27109","article-title":"Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine","volume":"93","author":"Abi Zeid Daou","year":"2021","journal-title":"J Med Virol"},{"issue":"7","key":"10.1016\/j.jdin.2022.01.011_bib43","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/cea.12760","article-title":"Immediate-type hypersensitivity to polyethylene glycols: a review","volume":"46","author":"Wenande","year":"2016","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"10.1016\/j.jdin.2022.01.011_bib44","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaip.2020.09.029","article-title":"Polyethylene glycol-induced systemic allergic reactions (anaphylaxis)","volume":"9","author":"Sellaturay","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.jdin.2022.01.011_bib45","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/cea.13874","article-title":"Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer\/BioNTech mRNA COVID-19 vaccine","volume":"51","author":"Sellaturay","year":"2021","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"10.1016\/j.jdin.2022.01.011_bib46","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3390\/vaccines9030221","article-title":"Allergic reactions to current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations","volume":"9","author":"Kounis","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"10.1016\/j.jdin.2022.01.011_bib47","first-page":"839","article-title":"Anaphylaxis is a rare reaction in COVID-19 vaccination","volume":"35","author":"Bellomo","year":"2021","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.1016\/j.jdin.2022.01.011_bib49","doi-asserted-by":"crossref","unstructured":"Park HJ, Montgomery CJ, Boggs LN. Anaphylaxis after the Covid-19 vaccine in a patient with cholinergic urticaria. Preprint. Posted online April 14, 2021. Mil Med. https:\/\/doi.org\/10.1093\/milmed\/usab138","DOI":"10.1093\/milmed\/usab138"},{"issue":"14","key":"10.1016\/j.jdin.2022.01.011_bib51","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1016\/j.vaccine.2020.02.046","article-title":"Immunization stress-related response\u2014redefining immunization anxiety-related reaction as an adverse event following immunization","volume":"38","author":"Gold","year":"2020","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.jdin.2022.01.011_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2021.100517","article-title":"COVID-19 vaccine-associated anaphylaxis: a statement of the World Allergy Organization Anaphylaxis Committee","volume":"14","author":"Turner","year":"2021","journal-title":"World Allergy Organ J"},{"issue":"3","key":"10.1016\/j.jdin.2022.01.011_bib53","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.jaci.2015.07.048","article-title":"Risk of anaphylaxis after vaccination in children and adults","volume":"137","author":"McNeil","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jdin.2022.01.011_bib54","article-title":"Attitudes towards vaccines and intention to vaccinate against COVID-19: implications for public health communications","volume":"1","author":"Paul","year":"2021","journal-title":"Lancet Reg Health Eur"},{"issue":"10287","key":"10.1016\/j.jdin.2022.01.011_bib55","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data","volume":"397","author":"Haas","year":"2021","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.jdin.2022.01.011_bib56","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jdin.2022.01.011_bib57","first-page":"302","article-title":"Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia","volume":"41","author":"Zhang","year":"2020","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.jdin.2022.01.011_bib58","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jdcr.2021.02.014","article-title":"\u201cCOVID arm\u201d: a reaction to the Moderna vaccine","volume":"10","author":"Wei","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jdin.2022.01.011_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2021.102093","article-title":"Delayed large local reaction to the adenovirus-vectored (ChAdOx1) vaccine","volume":"43","author":"Grobusch","year":"2021","journal-title":"Trav Med Infect Dis"},{"issue":"2","key":"10.1016\/j.jdin.2022.01.011_bib60","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","article-title":"T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial","volume":"27","author":"Ewer","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jdin.2022.01.011_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-88356-8","article-title":"Analysis of IgM, IgA, and IgG isotype antibodies directed against SARS-CoV-2 spike glycoprotein and ORF8 in the course of COVID-19","volume":"11","author":"Meinberger","year":"2021","journal-title":"Sci Rep"},{"issue":"13","key":"10.1016\/j.jdin.2022.01.011_bib62","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMc2102131","article-title":"Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2","volume":"384","author":"Blumenthal","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jdin.2022.01.011_bib63","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jdermsci.2021.06.006","article-title":"Clinical and histopathological views of morbilliform rash after COVID-19 mRNA vaccination mimic those in SARS-CoV-2 virus infection-associated cutaneous manifestations","volume":"103","author":"Ohsawa","year":"2021","journal-title":"J Dermatol Sci"},{"issue":"SI","key":"10.1016\/j.jdin.2022.01.011_bib64","doi-asserted-by":"crossref","first-page":"SI90","DOI":"10.1093\/rheumatology\/keab345","article-title":"Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series","volume":"60","author":"Furer","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.jdin.2022.01.011_bib65","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1111\/jocd.14035","article-title":"Herpes zoster following inactivated COVID-19 vaccine: a coexistence or coincidence?","volume":"20","author":"Bostan","year":"2021","journal-title":"J Cosmet Dermatol"},{"issue":"9","key":"10.1016\/j.jdin.2022.01.011_bib66","doi-asserted-by":"crossref","first-page":"5231","DOI":"10.1002\/jmv.27036","article-title":"Herpes zoster emergence following mRNA COVID-19 vaccine","volume":"93","author":"Eid","year":"2021","journal-title":"J Med Virol"},{"issue":"7","key":"10.1016\/j.jdin.2022.01.011_bib67","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1111\/jocd.14210","article-title":"20 Post-COVID-19 vaccine-related shingles cases seen at the Las Vegas Dermatology clinic and sent to us via social media","volume":"20","author":"Lee","year":"2021","journal-title":"J Cosmet Dermatol"},{"issue":"7830","key":"10.1016\/j.jdin.2022.01.011_bib68","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jdin.2022.01.011_bib69","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jdcr.2021.02.018","article-title":"Oral angiotensin-converting enzyme inhibitors for treatment of delayed inflammatory reaction to dermal hyaluronic acid fillers following COVID-19 vaccination-a model for inhibition of angiotensin II-induced cutaneous inflammation","volume":"10","author":"Munavalli","year":"2021","journal-title":"JAAD Case Rep"},{"issue":"2","key":"10.1016\/j.jdin.2022.01.011_bib70","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.bjid.2014.10.006","article-title":"Pityriasis rosea following human papillomavirus vaccination","volume":"19","author":"Drago","year":"2015","journal-title":"Braz J Infect Dis"},{"issue":"4","key":"10.1016\/j.jdin.2022.01.011_bib71","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1523-1747.2002.00200.x","article-title":"Pityriasis rosea is associated with systemic active infection with both human herpesvirus-7 and human herpesvirus-6","volume":"119","author":"Watanabe","year":"2002","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.jdin.2022.01.011_bib72","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jaad.2008.07.045","article-title":"Pityriasis rosea: an update with a critical appraisal of its possible herpesviral etiology","volume":"61","author":"Drago","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jdin.2022.01.011_bib73","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/archderm.1982.01650150048022","article-title":"Pityriasis rosea-like rash from captopril","volume":"118","author":"Wilkin","year":"1982","journal-title":"Arch Dermatol"}],"container-title":["JAAD International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328722000219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328722000219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T21:00:06Z","timestamp":1762981206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666328722000219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":71,"alternative-id":["S2666328722000219"],"URL":"https:\/\/doi.org\/10.1016\/j.jdin.2022.01.011","relation":{},"ISSN":["2666-3287"],"issn-type":[{"value":"2666-3287","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous reactions to COVID-19 vaccines: A review","name":"articletitle","label":"Article Title"},{"value":"JAAD International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdin.2022.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}